Human genetic susceptibility to infectious disease

Key Points

  • Common and rare human genetic variation influences susceptibility to infectious disease.

  • Genome-wide association studies have identified various strong associations between genetic polymorphisms and susceptibility to common infectious disease phenotypes, such as HIV-1, hepatitis B and C viruses, dengue, malaria, tuberculosis, leprosy, meningococcal disease and prion disease.

  • Studies have confirmed an important role for human leukocyte antigen (HLA) variation in susceptibility to many, but not all, common infectious diseases.

  • Application of genome-wide approaches to African populations is challenging, which reflects in part the high levels of ethnic diversity in Africa and a lack of population-specific genotyping arrays.

  • An increasing number of rare, single-gene defects have been described in association with susceptibility to a narrow range of different pathogens in otherwise healthy individuals.

  • Examples of mutations associated with such 'selective' immunodeficiencies include: interleukin-12–interleukin-23–interferon-γ (IFNγ) pathway defects and susceptibility to mycobacterial disease; Toll-like receptor (TLR)–nuclear factor-κB pathway defects and invasive pneumococcal disease; and TLR3–IFNα–IFNβ pathway mutations and herpes simplex viral encephalitis.

  • Both common and rare variants in the same molecular pathway may underlie related infectious disease phenotypes.

  • The relative contributions of common and rare variants to infectious disease susceptibility at the individual and population level are currently unknown. The application of next-generation sequencing technology is likely to define the genetic architecture of infectious disease.

Abstract

Recent genome-wide studies have reported novel associations between common polymorphisms and susceptibility to many major infectious diseases in humans. In parallel, an increasing number of rare mutations underlying susceptibility to specific phenotypes of infectious disease have been described. Together, these developments have highlighted a key role for host genetic variation in determining the susceptibility to infectious disease. They have also provided insights into the genetic architecture of infectious disease susceptibility and identified immune molecules and pathways that are directly relevant to the human host defence.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Genetic variation in TLR signalling and susceptibility to infectious disease.

References

  1. 1

    Kaufman, S. H. E. Robert Koch, the Nobel prize, and the ongoing threat of tuberculosis. N. Engl. J. Med. 353, 2423–2426 (2005).

    Google Scholar 

  2. 2

    Comstock, G. W. Tuberculosis in twins: a re-analysis of the Prophit survey. Am. Rev. Respir. Dis. 117, 621–624 (1978).

    CAS  PubMed  Google Scholar 

  3. 3

    Misch, E., Berrington, W. R., Vary, J. C. & Hawn, T. R. Leprosy and the human genome. Microbiol. Mol. Biol. Rev. 74, 589–620 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  4. 4

    Herndon, C. N. & Jennings, R. G. A twin family study on susceptibility to poliomyelitis. Am. J. Hum. Genet. 3, 17–46 (1951).

    CAS  PubMed  PubMed Central  Google Scholar 

  5. 5

    Lin, T. M. et al. Hepatitis B virus markers in Chinese twins. Anticancer Res. 9, 737–741 (1989).

    CAS  PubMed  Google Scholar 

  6. 6

    van der Eijk, E. A., van de Vosse, E., Vandenbroucke, J. P. & van Dissel, J. T. Heredity versus environment in tuberculosis in twins. Am. J. Respir. Crit. Care Med. 176, 1281–1288 (2007).

    PubMed  Google Scholar 

  7. 7

    Sorensen, T. I. A., Nielsen, G. G., Andersen, P. K. & Teasdale, T. W. Genetic and environmental influences on premature death in adult adoptees. New Engl. J. Med. 318, 727–732 (1988). A landmark study of adoptees that suggests that a host genetic component contributes significantly to the risk of death from infectious disease.

    CAS  PubMed  Google Scholar 

  8. 8

    Gingles, N. A. et al. Role of genetic resistance in invasive pneumococcal infection: identification and study of susceptibility and resistance in inbred mouse strains. Infect. Immun. 69, 426–434 (2001).

    CAS  PubMed  PubMed Central  Google Scholar 

  9. 9

    Cooke, G. C. & Hill, A. V. S. Genetics of susceptibility to human infectious disease. Nature Rev. Genet. 2, 967–977 (2001).

    CAS  PubMed  Google Scholar 

  10. 10

    Hill, A. V. Aspects of genetic susceptibility to human infectious diseases. Annu. Rev. Genet. 40, 469–486 (2006).

    CAS  Google Scholar 

  11. 11

    Burgner, D., Jamieson, S. E. & Blackwell, J. M. Genetic susceptibility to infectious diseases: big is beautiful, but will bigger be even better? Lancet Infect. Dis. 6, 653–663 (2006).

    CAS  PubMed  PubMed Central  Google Scholar 

  12. 12

    Stein, C. M. Genetic epidemiology of tuberculosis susceptibility: impact of study design. PLoS Pathog. 7, e1001189 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  13. 13

    An, P. & Winkler, C. A. Host genes associated with HIV/AIDS: advances in gene discovery. Trends Genet. 26, 119–131 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  14. 14

    Brouwer, M. C., Read, R. C. & van de Beek, D. Host genetics and outcome in meningococcal disease: a systematic review and meta-analysis. Lancet Infect. Dis. 10, 262–274 (2010).

    CAS  PubMed  Google Scholar 

  15. 15

    Brouwer, M. C. et al. Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis. Lancet Infect. Dis. 9, 31–44 (2009).

    CAS  PubMed  Google Scholar 

  16. 16

    The International HapMap Consortium. A haplotype map of the human genome. Nature 437, 1299–1320 (2005).

  17. 17

    The International HapMap Consortium. A second generation human haplotype map of over 3.1 million SNPs. Nature 449, 851–861 (2007).

  18. 18

    McCarthy, M. I. et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nature Rev. Genet. 9, 356–369 (2008).

    CAS  PubMed  Google Scholar 

  19. 19

    The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661–678 (2007).

  20. 20

    Manolio, T. Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med. 363, 166–176 (2010).

    CAS  PubMed  Google Scholar 

  21. 21

    Gloyn, A. et al. Variation across the allele frequency spectrum. Nature Genet. 42, 648–650 (2010).

    CAS  PubMed  Google Scholar 

  22. 22

    McClellan, J. & King, M.-C. Genetic heterogeneity in human disease. Cell 141, 210–217 (2010).

    CAS  PubMed  Google Scholar 

  23. 23

    Cirulli, E. & Goldstein, D. B. Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nature Rev. Genet. 11, 415–425 (2010).

    CAS  PubMed  Google Scholar 

  24. 24

    Kraft, P. & Hunter, D. J. Genetic risk prediction – are we there yet? N. Engl. J. Med. 360, 1701–1703 (2009).

    CAS  PubMed  Google Scholar 

  25. 25

    Fellay, J., Shianna, K. V., Telenti, A. & Goldstein, D. B. Host genetics and HIV-1: the final phase? PLoS Pathog. 6, 10 (2010).

    Google Scholar 

  26. 26

    Dean, M. et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273, 1856–1862 (1996).

    CAS  Google Scholar 

  27. 27

    Martin, M. P. et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 282, 1907–1911 (1998).

    CAS  PubMed  Google Scholar 

  28. 28

    Smith, M. W. et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science 277, 959–965 (1997).

    CAS  PubMed  Google Scholar 

  29. 29

    Huang, Y. et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Med. 2, 1240–1243 (1996).

    CAS  PubMed  Google Scholar 

  30. 30

    Hendel, H. et al. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J. Immunol. 162, 6942–6946 (1999).

    CAS  PubMed  Google Scholar 

  31. 31

    Flores-Villanueva, P. O. et al. Associations of MHC ancestral haplotypes with resistance/susceptibility to AIDS disease development. J. Immunol. 170, 1925–1929 (2003).

    CAS  PubMed  Google Scholar 

  32. 32

    Carrington, M., Martin, M. P. & van Bergen, J. KIR-HLA intercourse in HIV disease. Trends Microbiol. 16, 620–627 (2008).

    CAS  PubMed  PubMed Central  Google Scholar 

  33. 33

    Fellay, J. et al. Common genetic variation and the control of HIV-1 in humans. PLoS Genet. 5, e1000791 (2009).

    PubMed  PubMed Central  Google Scholar 

  34. 34

    Fellay, J. et al. A whole-genome association study of major determinants for host control of HIV-1. Science 317, 944–947 (2007). The first GWAS of an infectious disease.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. 35

    The International HIV Controllers Study. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330, 1551–1557 (2010). A large GWAS of HIV-1 controllers and progressors that extends our understanding of previous HLA associations with HIV-1 control and identifies the specific amino acid positions underlying these signals.

  36. 36

    Petrovski, S. et al. Common human genetic variants and HIV-1 susceptibility: a genome-wide survey in a homogeneous African population. AIDS 25, 513–518 (2011).

    PubMed  PubMed Central  Google Scholar 

  37. 37

    Joubert, B. R. et al. A whole genome association study of mother-to-child transmission of HIV in Malawi. Genome Med. 2, 17 (2010).

    PubMed  PubMed Central  Google Scholar 

  38. 38

    Pelak, K. et al. Host determinants of HIV-1 control in African Americans. J. Infect. Dis. 201, 1141–1149 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  39. 39

    Dalmasso, C. et al. Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS genome wide association 01 study. PLoS ONE 3, e3907 (2008).

    PubMed  PubMed Central  Google Scholar 

  40. 40

    Herbeck, J. T. et al. Multistage genomewide association study identifies a locus at 1q41 associated with rate of HIV-1 disease progression to clinical AIDS. J. Infect. Dis. 210, 618–626 (2010).

    Google Scholar 

  41. 41

    Troyer, J. L. et al. Genome-wide association study implicates PARD3B-based AIDS restriction. J. Infect. Dis. 203, 1491–1502 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  42. 42

    Limou, S. et al. Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS genomewide association study 02). J. Infect. Dis. 199, 419–426 (2009).

    PubMed  Google Scholar 

  43. 43

    Limou, S. et al. Multiple-cohort genetic association study reveals CXCR6 as a new chemokine receptor involved in long-term nonprogression to AIDS. J. Infect. Dis. 202, 908–915 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  44. 44

    Le Clerc, S. et al. Genomewide association study of a rapid progression cohort identifies new susceptibility alleles for AIDS (ANRS genomewide association study 03). J. Infect. Dis. 200, 1194–1201 (2009).

    CAS  PubMed  Google Scholar 

  45. 45

    de Roda Husman, A. M. et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann. Intern. Med. 127, 882–890 (1997).

    CAS  PubMed  Google Scholar 

  46. 46

    Liu, R. et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86, 367–377 (1996).

    CAS  Google Scholar 

  47. 47

    Samson, M. et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382, 722–725 (1996).

    CAS  Google Scholar 

  48. 48

    Salkowitz, J. R. et al. CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro. Clin. Immunol. 108, 234–240 (2003).

    CAS  PubMed  PubMed Central  Google Scholar 

  49. 49

    Rizzardi, G. P. et al. CCR2 polymorphism and HIV disease. Swiss HIV Cohort. Nature Med. 4, 252–253 (1998).

    CAS  PubMed  Google Scholar 

  50. 50

    Kosmrlj, A. et al. Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature 465, 350–354 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  51. 51

    Thomas, R. et al. HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nature Genet. 41, 1290–1294 (2009).

    CAS  PubMed  Google Scholar 

  52. 52

    Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399–401 (2009).

    CAS  Google Scholar 

  53. 53

    Rauch, A. et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138, 1338–1345 (2010).

    CAS  PubMed  Google Scholar 

  54. 54

    Suppiah, V. et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nature Genet. 41, 1100–1104 (2009).

    CAS  PubMed  Google Scholar 

  55. 55

    Tanaka, Y. et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nature Genet. 41, 1105–1109 (2009).

    CAS  PubMed  Google Scholar 

  56. 56

    Ochi, H. et al. IL-28B predicts response to chronic hepatitis C therapy – fine-mapping and replication study in Asian populations. J. Gen. Virol. 92, 1071–1081 (2011). References 52–56 report strong genomic associations with response to IFNα treatment of hepatitis C. Together, these papers provide a rare example of a genetic association that may rapidly translate into clinical benefit.

    CAS  PubMed  Google Scholar 

  57. 57

    Thomas, D. L. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798–801 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  58. 58

    O'Brien, T. R. Interferon-alfa, interferon-λ and hepatitis C. Nature Genet. 41, 1048–1050 (2009).

    CAS  PubMed  Google Scholar 

  59. 59

    Marcello, T. et al. Interferons α and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131, 1887–1898 (2006).

    PubMed  Google Scholar 

  60. 60

    Kamatani, Y. et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nature Genet. 41, 591–595 (2009).

    CAS  PubMed  Google Scholar 

  61. 61

    An, P. et al. A common HLA-DPA1 variant is a major determinant of hepatitis B virus clearance in Han Chinese. J. Infect. Dis. 203, 943–947 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  62. 62

    Guo, X. et al. Strong influence of human leukocyte antigen (HLA)-DP gene variants on development of persistent chronic hepatitis B virus carriers in the Han Chinese population. Hepatology 53, 422–428 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  63. 63

    Wang, L. et al. Evaluation of genetic susceptibility loci for chronic hepatitis B in Chinese: two independent case-control studies. PLoS ONE 6, e17608 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  64. 64

    O'Brien, T. R. et al. Risk alleles for chronic hepatitis B are associated with decreased mRNA expression of HLA-DPA1 and HLA-DPB1 in normal human liver. Genes Immun. 12, 428–433 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  65. 65

    Khor, CC. et al. Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1. Nature Genet. 43, 1139–1141 (2011). The first GWAS for susceptibility to dengue. It identifies robust, novel associations with variants in MICB and PLCE1.

    CAS  PubMed  Google Scholar 

  66. 66

    Champsaur, M. & Lanier, L. L. Effect of NKG2D ligand expression on host immune responses. Immunol. Rev. 235, 267–285 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  67. 67

    Hoang, L. T. et al. The early whole-blood transcriptional signature of dengue virus and features associated with progression to dengue shock syndrome in Vietnamese children and young adults. J. Virol. 84, 12982–12994 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  68. 68

    Hinkes, B. et al. Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nature Genet. 38, 1397–1405 (2006).

    CAS  PubMed  Google Scholar 

  69. 69

    Malaria Genomic Epidemiology Network. A global network for investigating the genomic epidemiology of malaria. Nature 456, 732–737 (2008).

  70. 70

    Jallow, M. et al. Genome-wide and fine-resolution association analysis of malaria in West Africa. Nature Genet. 41, 657–665 (2009). This study of severe malaria in The Gambia provides valuable insights into the challenges involved in performing effective GWASs in African populations.

    CAS  PubMed  Google Scholar 

  71. 71

    Allison, A. C. Protection afforded by sickle-cell trait against subtertain malarial infection. BMJ 1, 290–294 (1954).

    CAS  PubMed  Google Scholar 

  72. 72

    Thye, T. et al. Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18q11.2. Nature Genet. 42, 739–741 (2010).

    CAS  PubMed  Google Scholar 

  73. 73

    Mira, M. T. et al. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature 427, 636–640 (2004).

    CAS  PubMed  Google Scholar 

  74. 74

    Alcaïs, A. et al. Stepwise replication identifies a low-producing lymphotoxin-α allele as a major risk factor for early-onset leprosy. Nature Genet. 39, 517–522 (2007).

    PubMed  Google Scholar 

  75. 75

    Geluk, A. & Ottenhoff, T. H. HLA and leprosy in the pre and postgenomic eras. Hum. Immunol. 67, 439–445 (2006).

    CAS  PubMed  Google Scholar 

  76. 76

    Zhang, F. R. et al. Genomewide association study of leprosy. N. Engl. J. Med. 361, 2609–2618 (2009). The first GWAS of leprosy susceptibility. It identifies multiple strong associations, many of which cluster in innate immune pathways and overlap with susceptibility loci for Crohn's disease.

    CAS  PubMed  Google Scholar 

  77. 77

    Schurr, E. & Gros, P. A common genetic fingerprint in leprosy and Crohn's disease? N. Engl. J. Med. 361, 2666–2668 (2009).

    CAS  PubMed  Google Scholar 

  78. 78

    Wong, S. H. et al. Leprosy and the adaptation of human Toll-like receptor 1. PLoS Pathog. 6, e1000979 (2010).

    PubMed  PubMed Central  Google Scholar 

  79. 79

    Wong, S. H., Hill, A. V. & Vannberg, F. O. Genomewide association study of leprosy. N. Engl. J. Med. 362, 1446–1447 (2010).

    CAS  PubMed  Google Scholar 

  80. 80

    Berrington, W. R. et al. Common polymorphisms in the NOD2 gene region are associated with leprosy and its reactive states. J. Infect. Dis. 201, 1422–1435 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  81. 81

    Kanneganti, T.-D., Lamkanfi, M. & Nunez, G. Intracellular NOD-like receptors in host defense and disease. Immunity 27, 549–559 (2007).

    CAS  Google Scholar 

  82. 82

    Franke, A. et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nature Genet. 42, 1118–1125 (2010).

    CAS  PubMed  Google Scholar 

  83. 83

    Marks, D. J. B., Rahman, F. Z., Sewell, G. W. & Segal, A. W. Crohn's disease: an immune deficiency state. Clin. Rev. Allergy Immunol. 38, 20–31 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  84. 84

    Haralambous, E. et al. Factor H, a regulator of complement activity, is a major determinant of meningococcal disease susceptibility in UK Caucasian patients. Scand. J. Infect. Dis. 38, 764–771 (2006).

    CAS  PubMed  Google Scholar 

  85. 85

    Davila, S. et al. Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nature Genet. 42, 772–776 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  86. 86

    Hughes, A. E. et al. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nature Genet. 38, 1173–1177 (2006).

    CAS  PubMed  Google Scholar 

  87. 87

    Degn, S. E., Jensenius, J. C. & Thiel, S. Disease-causing mutations in genes of the complement system. Am. J. Hum. Genet. 88, 689–705 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  88. 88

    Zeidler, M., Stewart, G., Cousens, S. N., Estibeiro, K. & Will, R. G. Codon 129 genotype and new variant CJD. Lancet 350, 668 (1997).

    CAS  PubMed  Google Scholar 

  89. 89

    Mead, S. et al. Balancing selection at the prion protein gene consistent with prehistoric kurulike epidemics. Science 300, 640–643 (2003).

    CAS  PubMed  Google Scholar 

  90. 90

    Gambetti, P., Kong, Q., Zou, W., Parchi, P. & Chen, S. G. Sporadic and familial CJD: classification and characterisation. Br. Med. Bull. 66, 213–239 (2003).

    CAS  PubMed  Google Scholar 

  91. 91

    Mead, S. et al. Genetic risk factors for variant Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurol. 8, 57–66 (2009).

    PubMed  PubMed Central  Google Scholar 

  92. 92

    Kaski, D. et al. Variant CJD in an individual heterozygous for PRNP codon 129. Lancet 374, 2128 (2009).

    PubMed  Google Scholar 

  93. 93

    Casanova, J. L. & Abel, L. Primary immunodeficiencies: a field in its infancy. Science 317, 617–619 (2007). This review introduces a paradigm shift in primary immunodeficiency by describing the concept of 'selective' immunodeficiency.

    CAS  PubMed  Google Scholar 

  94. 94

    Picard, C. et al. Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine 89, 403–425 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  95. 95

    van de Vosse, E., van Dissel, J. T. & Ottenhoff, T. H. Genetic deficiencies of innate immune signalling in human infectious disease. Lancet Infect. Dis. 9, 688–698 (2009).

    PubMed  Google Scholar 

  96. 96

    Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nature Immunol. 11, 373–384 (2010).

    CAS  Google Scholar 

  97. 97

    von Bernuth, H. et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 321, 691–696 (2008).

    CAS  PubMed  PubMed Central  Google Scholar 

  98. 98

    Zonana, J. et al. A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-γ (NEMO). Am. J. Hum. Genet. 67, 1555–1562 (2000).

    CAS  PubMed  PubMed Central  Google Scholar 

  99. 99

    Doffinger, R. et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-κB signaling. Nature Genet. 27, 277–285 (2001).

    CAS  PubMed  Google Scholar 

  100. 100

    Picard, C. et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299, 2076–2079 (2003). This study, together with reference 97, provides clear evidence that single-gene mutations disrupting TLR and IL-1 receptor signalling may result in a narrow spectrum immunodeficiency in otherwise healthy children.

    CAS  Google Scholar 

  101. 101

    Courtois, G. et al. A hypermorphic IκBα mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J. Clin. Invest. 112, 1108–1115 (2003).

    CAS  PubMed  PubMed Central  Google Scholar 

  102. 102

    Janssen, R. et al. The same IκBα mutation in two related individuals leads to completely different clinical syndromes. J. Exp. Med. 200, 559–568 (2004).

    CAS  PubMed  PubMed Central  Google Scholar 

  103. 103

    Medvedev, A. E. et al. Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J. Exp. Med. 198, 521–531 (2003).

    CAS  PubMed  PubMed Central  Google Scholar 

  104. 104

    Misch, E. A. & Hawn, T. R. Toll-like receptor polymorphisms and susceptibility to human disease. Clin. Sci. 114, 347–360 (2008).

    PubMed  Google Scholar 

  105. 105

    Chapman, S. J. et al. IκB genetic polymorphisms and invasive pneumococcal disease. Am. J. Respir. Crit. Care Med. 176, 181–187 (2007).

    CAS  PubMed  Google Scholar 

  106. 106

    Chapman, S. J. et al. NFKBIZ polymorphisms and susceptibility to pneumococcal disease in European and African populations. Genes Immun. 11, 319–325 (2010).

    CAS  PubMed  Google Scholar 

  107. 107

    Chapman, S. J. et al. Common NFKBIL2 polymorphisms and susceptibility to pneumococcal disease: a genetic association study. Crit. Care 14, R227 (2010).

    PubMed  PubMed Central  Google Scholar 

  108. 108

    Khor, C. C. et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nature Genet. 39, 523–528 (2007).

    CAS  PubMed  PubMed Central  Google Scholar 

  109. 109

    Kumpf, O. et al. Influence of genetic variations in TLR4 and TIRAP/Mal on the course of sepsis and pneumonia and cytokine release: an observational study in three cohorts. Crit. Care 14, R103 (2010).

    PubMed  PubMed Central  Google Scholar 

  110. 110

    Hamann, L. et al. Low frequency of the TIRAP S180L polymorphism in Africa, and its potential role in malaria, sepsis, and leprosy. BMC Med. Genet. 10, 65 (2009).

    PubMed  PubMed Central  Google Scholar 

  111. 111

    Nejentsev, S. et al. Analysis of association of the TIRAP (MAL) S180L variant and tuberculosis in three populations. Nature Genet. 40, 261–262; author reply 262–263 (2008).

    CAS  PubMed  PubMed Central  Google Scholar 

  112. 112

    Hawn, T. R. et al. A polymorphism in Toll-interleukin 1 receptor domain containing adaptor protein is associated with susceptibility to meningeal tuberculosis. J. Infect. Dis. 194, 1127–1134 (2006).

    CAS  PubMed  PubMed Central  Google Scholar 

  113. 113

    Castiblanco, J. et al. TIRAP (MAL) S180L polymorphism is a common protective factor against developing tuberculosis and systemic lupus erythematosus. Infect. Genet. Evol. 8, 541–544 (2008).

    CAS  PubMed  PubMed Central  Google Scholar 

  114. 114

    Dissanayeke, S. B. et al. Polymorphic variation in TIRAP is not associated with susceptibility to childhood TB but may determine susceptibility to TBM in some ethnic groups. PLoS ONE 4, e6698 (2009).

    PubMed  PubMed Central  Google Scholar 

  115. 115

    Selvaraj, P. et al. Toll-like receptor and TIRAP gene polymorphisms in pulmonary tuberculosis patients of South India. Tuberculosis 90, 306–310 (2010).

    CAS  PubMed  Google Scholar 

  116. 116

    Ladhani, S. N. et al. Association between single-nucleotide polymorphisms in Mal/TIRAP and interleukin-10 genes and susceptibility to invasive haemophilus influenzae serotype b infection in immunized children. Clin. Infect. Dis. 51, 761–767 (2010).

    CAS  PubMed  Google Scholar 

  117. 117

    Ferwerda, B. et al. Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock. Proc. Natl Acad. Sci. USA 106, 10272–10277 (2009).

    CAS  Google Scholar 

  118. 118

    Casrouge, A. et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 314, 308–312 (2006).

    CAS  PubMed  PubMed Central  Google Scholar 

  119. 119

    Zhang, S. Y. et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 317, 1522–1527 (2007).

    CAS  Google Scholar 

  120. 120

    Perez de Diego, R. et al. Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis. Immunity 33, 400–411 (2010). References 118–120 provide the first demonstration that selective primary immunodeficiency underlies susceptibility to HSE.

    CAS  PubMed  Google Scholar 

  121. 121

    Blackwell, J. M., Jamieson, S. E. & Burgner, D. HLA and infectious diseases. Clin. Microbiol. Rev. 22, 370–385 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  122. 122

    Smirnova, I. et al. Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility. Proc. Natl Acad. Sci. USA 100, 6075–6080 (2003).

    CAS  PubMed  Google Scholar 

  123. 123

    Macchi, P. et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377, 65–68 (1995).

    CAS  PubMed  Google Scholar 

  124. 124

    Russell, S. M. et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270, 797–800 (1995).

    CAS  PubMed  PubMed Central  Google Scholar 

  125. 125

    Dupuis, S. et al. Impaired response to interferon-α/β and lethal viral disease in human STAT1 deficiency. Nature Genet. 33, 388–391 (2003).

    CAS  PubMed  Google Scholar 

  126. 126

    Liu, L. et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J. Exp. Med. 208, 1635–1648 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  127. 127

    van de Veerdonk, F. L. et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N. Engl. J. Med. 365, 54–61 (2011).

    CAS  PubMed  Google Scholar 

  128. 128

    Holland, S. M. et al. STAT3 mutations in the hyper-IgE syndrome. N. Engl. J. Med. 357, 1608–1619 (2007).

    CAS  PubMed  Google Scholar 

  129. 129

    Minegishi, Y. et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 448, 1058–1062 (2007).

    CAS  PubMed  Google Scholar 

  130. 130

    Minegishi, Y. et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25, 745–755 (2006).

    CAS  PubMed  Google Scholar 

  131. 131

    Khor, C. C. et al. CISH and susceptibility to infectious diseases. N. Engl. J. Med. 362, 2092–2101 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  132. 132

    Gu, Y. et al. Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. Nature 458, 1039–1042 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  133. 133

    Alcaïs, A., Abel, L. & Casanova, J. L. Human genetics of infectious diseases: between proof of principle and paradigm. J. Clin. Invest. 119, 2506–2514 (2009).

    PubMed  PubMed Central  Google Scholar 

  134. 134

    Frazer, K. A., Murray, S. S., Schork, N. J. & Topol, E. J. Human genetic variation and its contribution to complex traits. Nature Rev. Genet. 10, 241–251 (2009).

    CAS  PubMed  Google Scholar 

  135. 135

    Teo, Y. et al. Methodological challenges of genome-wide association analysis in Africa. Nature Rev. Genet. 11, 149–160 (2010).

    CAS  PubMed  Google Scholar 

  136. 136

    Rosenberg, N. et al. Genome-wide association studies in diverse populations. Nature Rev. Genet. 11, 356–366 (2010).

    CAS  PubMed  Google Scholar 

  137. 137

    The 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 467, 1061–1073 (2010).

  138. 138

    Zhang, S.-Y. et al. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-a/β, IFN-γ, and IFN-λ in host defense. Immunol. Rev. 226, 29–40 (2008).

    CAS  Google Scholar 

  139. 139

    Maródi, L. & Notarangelo, L. D. Immunological and genetic bases of new primary immunodeficiencies. Nature Rev. Immunol. 7, 851–861 (2007).

    Google Scholar 

  140. 140

    Cooke, G. S. et al. Polymorphism within the interferon-γ/receptor complex is associated with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 174, 339–343 (2006).

    CAS  PubMed  Google Scholar 

  141. 141

    Vannberg, F. O., Chapman, S. J. & Hill, A. V. Human genetic susceptibility to intracellular pathogens. Immunol. Rev. 240, 105–116 (2011).

    CAS  PubMed  Google Scholar 

  142. 142

    Pacheco, A. G., Cardoso, C. C. & Moraes, M. O. IFNG +874T/A, IL10 -1082G/A and TNF -308G/A polymorphisms in association with tuberculosis susceptibility: a meta-analysis study. Hum. Genet. 123, 477–484 (2008).

    CAS  PubMed  Google Scholar 

  143. 143

    Awomoyi, A. A. et al. No association between interferon-γ receptor-1 gene polymorphism and pulmonary tuberculosis in a Gambian population sample. Thorax 59, 291–294 (2004).

    CAS  PubMed  PubMed Central  Google Scholar 

  144. 144

    Bustamante, J. et al. Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease. Nature Immunol. 12, 213–221 (2011).

    CAS  Google Scholar 

  145. 145

    Hambleton, S. et al. IRF8 mutations and human dendritic-cell immunodeficiency. N. Engl. J. Med. 365, 127–138 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  146. 146

    Le Pendu, J., Ruvoën-Clouet, N., Kindberg, E. & Svensson, L. Mendelian resistance to human norovirus infections. Semin. Immunol. 18, 375–386 (2006).

    CAS  PubMed  Google Scholar 

  147. 147

    Aspholm-Hurtig, M. et al. Functional adaptation of BabA, the H. pylori ABO blood group antigen binding adhesin. Science 305, 519–522 (2004).

    CAS  PubMed  Google Scholar 

  148. 148

    Lindesmith, L. C. et al. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med. 5, e31 (2008).

    PubMed  PubMed Central  Google Scholar 

  149. 149

    Gagneux, S. et al. Variable host–pathogen compatibility in Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 103, 2869–2873 (2006).

    CAS  PubMed  Google Scholar 

  150. 150

    Kumar, D. et al. Genome-wide analysis of the host intracellular network that regulates survival of Mycobacterium tuberculosis. Cell 140, 731–743 (2010).

    CAS  PubMed  Google Scholar 

  151. 151

    Di Pietrantonio, T., Correa, J. A., Orlova, M., Behr, M. A. & Schurr, E. Joint effects of host genetic background and mycobacterial pathogen on susceptibility to infection. Infect. Immun. 79, 2372–2378 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  152. 152

    Caws, M. et al. The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog. 4, e1000034 (2008).

    PubMed  PubMed Central  Google Scholar 

  153. 153

    Monot, M. et al. On the origin of leprosy. Science 308, 1040–1042 (2005).

    CAS  PubMed  Google Scholar 

  154. 154

    Schurr, E. Is susceptibility to tuberculosis acquired or inherited? J. Intern. Med. 261, 106–111 (2007).

    CAS  PubMed  Google Scholar 

  155. 155

    Lazzaro, B. P., Sceurman, B. K. & Clark, A. G. Genetic basis of natural variation in D. melanogaster antibacterial immunity. Science 303, 1873–1876 (2004).

    CAS  PubMed  Google Scholar 

  156. 156

    McDermid, J. M. et al. Mortality in HIV infection is independently predicted by host iron status and SLC11A1 and HP genotypes, with new evidence of a gene-nutrient interaction. Am. J. Clin. Nutr. 90, 225–233 (2009).

    CAS  PubMed  Google Scholar 

  157. 157

    Mallal, S. et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359, 727–732 (2002).

    CAS  PubMed  Google Scholar 

  158. 158

    Martin, A. M. et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl Acad. Sci. USA 101, 4180–4185 (2004).

    CAS  PubMed  Google Scholar 

  159. 159

    Young, B. et al. First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. AIDS 22, 1673–1675 (2008).

    CAS  PubMed  Google Scholar 

  160. 160

    Colombo, S. et al., The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. J. Infect. Dis. 198, 864–867 (2008).

    CAS  PubMed  Google Scholar 

  161. 161

    Hetherington, S. et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359, 1121–1122 (2002).

    CAS  PubMed  Google Scholar 

  162. 162

    Clark, P. J., Thompson, A. L. & McHutchison, J. G. IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Am. J. Gastroenterol. 106, 38–45 (2011).

    CAS  PubMed  Google Scholar 

  163. 163

    Fellay, J. et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 464, 405–408 (2010).

    CAS  PubMed  Google Scholar 

  164. 164

    Ochi, H. et al. Inosine triphosphate pyrophophatase polymorphism affects ribavirin-induced anaemia and outcome of therapy – a genome-wide study of Japanese hepatitis C virus patients. Gastroenterology 139, 1190–1197 (2010).

    CAS  PubMed  Google Scholar 

  165. 165

    Tanaka, Y. et al. Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hum. Mol. Genet. 20, 3507–3516 (2011).

    CAS  PubMed  Google Scholar 

  166. 166

    Hitotsumatsu, O. et al. The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity 28, 381–390 (2008).

    CAS  PubMed  PubMed Central  Google Scholar 

  167. 167

    Sprong, T. et al. Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections. Blood 107, 4865–4870 (2006).

    CAS  PubMed  Google Scholar 

  168. 168

    Fijen, C. A., Kuijper, E. J., te Bulte, M. T., Daha, M. R. & Dankert, J. Assessment of complement deficiency in patients with meningococcal disease in The Netherlands. Clin. Infect. Dis. 28, 98–105 (1999).

    CAS  PubMed  Google Scholar 

  169. 169

    Skattum, L., van Deuren, M., van der Poll, T. & Truedsson, L. Complement deficiency states and associated infections. Mol. Immunol. 48, 1643–1655 (2011).

    CAS  PubMed  Google Scholar 

  170. 170

    Jonsson, G. et al. Hereditary C2 deficiency in Sweden: frequent occurrence of invasive infection, atherosclerosis, and rheumatic disease. Medicine 84, 23–34 (2005).

    PubMed  Google Scholar 

  171. 171

    Byun, M. et al. Whole-exome sequencing-based discovery of STIM1 deficiency in a child with fatal classic Kaposi sarcoma. J. Exp. Med. 207, 2307–2312 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  172. 172

    Ramoz, N. et al. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nature Genet. 32, 579–581 (2002).

    CAS  PubMed  Google Scholar 

  173. 173

    Lindesmith, L. et al. Human susceptibility and resistance to Norwalk virus infection. Nature Med. 9, 548–553 (2003).

    CAS  PubMed  Google Scholar 

  174. 174

    Thorven, M. et al. A homozygous nonsense mutation (428G-->A) in the human secretor (FUT2) gene provides resistance to symptomatic norovirus (GGII) infections. J. Virol. 79, 15351–15355 (2005).

    CAS  PubMed  PubMed Central  Google Scholar 

  175. 175

    Miller, L. H., Mason, S. J., Clyde, D. F. & McGinniss, M. H. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N. Engl. J. Med. 295, 302–304 (1976).

    CAS  PubMed  Google Scholar 

  176. 176

    Glocker, E. O. et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N. Engl. J. Med. 361, 1727–1735 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  177. 177

    Puel, A. et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332, 65–68 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Research in the authors' laboratory is funded by the Wellcome Trust, the UK Medical Research Council and the UK National Institute for Health Research (NIHR) Oxford Biomedical Research Centre.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Stephen J. Chapman.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links

Related links

FURTHER INFORMATION

MalariaGEN

1000 Genomes Project

Nature Reviews Genetics series on Genome-wide association studies

Glossary

Power

The probability of correctly rejecting the null hypothesis when it is truly false. In genetic association studies, power is determined by the sample size, allele frequency, magnitude of effect and significance threshold, and can be considered as the probability that the study will correctly detect a genuine association.

Population stratification

The presence in a population of several subpopulations that differ in their genetic characteristics, reflecting their different ancestral histories. Such systematic ancestry differences between cases and controls can confound genetic association studies, causing spurious disease associations.

Multiple testing

An analysis in which multiple independent hypotheses are tested within a single data set. Performing multiple independent tests increases the likelihood of a type I error and requires adjustment of the threshold significance level (P value); for example, by using the Bonferroni correction.

Principal components analysis

A statistical method that is used to simplify a complex data set by transforming a series of correlated variables into a smaller number of uncorrelated variables called principal components. It is commonly used to correct for stratification in genome-wide association studies.

'Common disease, common variant' hypothesis

This hypothesis states that the genetic variants that underlie complex disease are themselves common.

Heritability

The proportion of phenotypic variation in a given characteristic or state that is due to underlying genetic variation.

Human leukocyte antigens

(HLAs). Glycoproteins encoded by the major histocompatibility complex locus that are located on the surface of antigen-presenting cells and that present antigenic peptides to T cells.

Killer immunoglobulin-like receptors

Receptors expressed at the surface of natural killer (NK) cells that regulate NK cell cytotoxic activity through specific interactions with HLA class I molecules.

Viral-load set point

The HIV RNA level in the blood during the asymptomatic period of HIV-1 infection. It fluctuates around a steady set-point value, although it is variable both within patients over time and among patients. High viral-load set points correlate with rapid disease progression.

Linkage disequilibrium

(LD). The occurrence of alleles together at frequencies greater than are expected by chance alone.

Major histocompatibility complex

(MHC). A large complex of tightly linked genes on human chromosome 6, many of which are involved in the immune response. The HLA genes are located within the MHC.

HIV-1 nonprogression

HIV-1 disease progression may be assessed by a number of measures, which can be used to define subgroups of individuals with long-term nonprogression. It can be defined, for example, as asymptomatic HIV-1 infection and a stable CD4+ T cell count for ten or more years in the absence of treatment.

HIV-1 controllers

A small subgroup of individuals infected with HIV-1 who maintain very low or undetectable plasma HIV viral loads in the absence of antiviral therapy.

Imputation

A statistical method that infers the genotype of untyped variants based on the known genotypes of a smaller number of nearby markers and the known linkage disequilibrium relationships in fully genotyped individuals (provided by HapMap reference data).

Hypovolaemic shock

A life-threatening condition in which fluid loss results in a reduction in the intravascular blood volume and inadequate tissue perfusion.

Conditional analysis

A form of statistical testing that considers the independent contributions of variants in a region of association containing multiple variants in linkage disequilibrium, in order to identify the most likely causal variant or variants.

Innate immunity

An immediate, non-specific and evolutionarily conserved ancient form of immune response to foreign infectious agents. It constitutes the first line of defence against invading organisms.

Crohn's disease

A type of inflammatory bowel disease characterized by granulomatous inflammation that may occur in any region of the gastrointestinal tract.

Complement

A complex protein cascade that is involved in both innate and adaptive immunity. Complement activation results in pathogen opsonization and cell lysis, and occurs through three different pathways: alternate, classical and lectin.

Respiratory burst

The rapid generation and release of reactive oxygen species that follows exposure of phagocytes (primarily neutrophils and macrophages) to microorganisms or inflammatory mediators.

Penetrance

The proportion of individuals with a given genotype who display a particular phenotype.

Odds ratio

A comparison of the odds of exposure to a susceptible genetic variant in cases versus controls.

Lipopolysaccharide

A Gram-negative bacterial cell wall component that is recognized by Toll-like receptor 4 and triggers a pro-inflammatory host response.

'Pathway-based' sequencing strategies

Joint analysis of variants within a group of related genes in the same biological pathway, as opposed to analysis of individual markers.

Whole-exome

The collection of protein-coding regions (exons) in the genome. It is widely presumed that most genetic variants that exert a large effect on disease susceptibility will be located in coding regions. Because these regions comprise only 1% of the human genome, whole-exome sequencing represents a potentially efficient strategy for the identification of rare, large-effect variants underlying disease.

Severe combined immunodeficiency

A range of primary immunodeficiencies due to severe defects in T cell (and often B cell) production and function and defective cytokine signalling that result in early-onset severe infections by a range of pathogens.

Chronic mucocutaneous candidiasis

Persistent or recurrent superficial infections of the skin, nails or mucous membranes by Candida species.

Hyper-IgE syndrome

A primary immunodeficiency characterized by eczema, greatly elevated serum levels of immunoglobulin E (IgE) and recurrent skin and pulmonary infections.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Chapman, S., Hill, A. Human genetic susceptibility to infectious disease. Nat Rev Genet 13, 175–188 (2012). https://doi.org/10.1038/nrg3114

Download citation

Further reading